Your session is about to expire
← Back to Search
Certolizumab + Chemotherapy + Nivolumab for Lung Cancer
Study Summary
This trial is testing whether adding the drug certolizumab to standard chemotherapy can help reduce inflammation and make the chemotherapy more effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently on medication for hepatitis B.I am currently being treated for an infection, but it's not thrush.You are allergic to Chinese hamster ovary cell products or any part of the nivolumab medication.I have active or untreated latent tuberculosis.I haven't taken any immune-weakening drugs in the last 2 weeks and don't expect to need any during the study.My lung cancer is in stage II-III and can be surgically removed.Your disease must be confirmed by a special test at MSKCC.I am allergic to ingredients in Certolizumab pegol.I am allergic to components in platinum-based chemotherapy.My bone marrow, liver, and kidneys are functioning well.I have previously used a TNF-alpha inhibitor.I do not have active hepatitis B.I have had cancer before, but it was unlikely to spread or be fatal.I have at least one tumor that can be measured.You are allergic to platinum-based medications.I am mostly able to care for myself.I do not have HIV, or if I do, it is under control with treatment.You have uncontrolled or symptomatic high levels of calcium in your blood.I have open, infected wounds on my skin.I have not received any live vaccines in the last 4 weeks and won't during or for 5 months after my nivolumab treatment.I haven't had major surgery in the last 4 weeks and don't expect to need one during the study.I haven't taken any immune-boosting drugs in the last 4 weeks or 5 half-lives of the drug.You need to have a negative pregnancy test within 14 days before starting the treatment.I don't have any health issues that would make it unsafe for me to take a new drug.I have not had a severe infection in the last 4 weeks.My NSCLC has a genetic change treatable with FDA-approved drugs.I have a history of lung scarring or inflammation not caused by infections.You have tested negative for tuberculosis.I currently have an active shingles infection.I have another cancer, but it won't affect this cancer treatment's safety or results.I haven't had serious heart problems or irregular heartbeats in the last 3 months.I have not taken any strong antibiotics in the last 2 weeks.You have a current or past autoimmune disease or immune deficiency.I am 18 years old or older.I have Hepatitis B or C.I am on medication for HIV or have AIDS.You tested negative for hepatitis B surface antigen (HBsAg) during screening.You've had serious allergic reactions to certain types of medications made from proteins.I have moderate to severe hearing loss.I have previously been treated with CD137 agonists or immune checkpoint inhibitors.I have had a previous transplant of stem cells or an organ.
- Group 1: Participants with resectable stage II-III lung cancers (Adenocarcinoma)
- Group 2: Participants with resectable stage II-III lung cancers (squamous cell carcinoma)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has Certolizumab been cleared by the FDA?
"While there is some clinical data supporting Certolizumab's safety, its efficacy has yet to be proven, so it received a score of 2."
Are new participants being permitted to join the research at this time?
"That is correct. The clinical trial mentioned is currently underway and looking for 60 individuals from 7 different locations. The information was published on October 19th, 2020 and was last edited on October 20th, 2020."
What medical conditions does Certolizumab target?
"Certolizumab is an effective medical treatment for patients with urinary bladder cancer, small cell lung cancer (sclc), and advanced testicular cancer."
How does Certolizumab compare to other treatments in similar clinical trials?
"City of Hope Comprehensive Cancer Center was the first to study certolizumab back in 1997 and, since then, 2581 trials have completed. As of now, there are 1479 ongoing studies, a majority of which are based in Uniondale, New jersey."
Share this study with friends
Copy Link
Messenger